Abstract
The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have